Medicxi VC specialist Medicxi has closed its oversubscribed €500m Fund V to support existing biopharmaceutical developers, and creating new companies across all development stages.
chokniti - Adobe StockSwiss biotech Virometix has raised US$15m in fresh funding to accelerate development of its lead pneumococcal vaccine candidate and advance its next-generation synthetic vaccine platform.
Scripta TherapeuticsOxford-based techbio startup Scripta Therapeutics has emerged from stealth with a biology-first platform targeting the master regulators of disease.
adobe stock photos - JustlightAstraZeneca’s baxdrostat cuts 24-hour systolic BP by 14mmHg in resistant hypertension, offering a novel mechanism and major market potential.
stock.adobe.photos.com - gaviAstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market.
adobe stock photos - AkuAku A landmark discovery by a team of South Korean scientists could transform the way RNA-based vaccines and therapeutics are developed and produced. Researchers led jointly by Professor V. Narry Kim and Professor Jin-Hong Kim have identified a series of viral RNA motifs that make conventional messenger RNA (mRNA) far more stable and efficient, potentially revolutionising RNA drug manufacturing.
Adobe stock photos - Dzmitry Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®) not only promote weight loss but also significantly reduce the risk of major cardiovascular events in patients with type 2 diabetes. Real-world evidence from the Technical University of Munich and Harvard Medical School shows up to 18% lower risk of heart attack and stroke, highlighting the growing potential of GLP-1 therapies in cardiometabolic care.
Adobe stock photos - Matthew Eli Lilly and Novo Nordisk cut US obesity drug prices under Trump’s MFN plan, offering Zepbound, Wegovy and others via Medicare, Medicaid and LillyDirect.
Parse BiosciencesBiotech leader QIAGEN NV announced the acquisition of Parse Biosciences for US$225M upfront, plus up to US$55M in milestone payments, expected to close by the end of 2025.
Boehringer IngelheimBoehringer Ingelheim has licenced global rights for CDR111, an antibody-based trispecific M-gager to treat autoimmune diseases from CDR-Life, Inc. CDR111 is an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset.